Reference pricing for pharmaceuticals: Is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?

Thomas A. Faunce*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    19 Citations (Scopus)

    Abstract

    Unless the federal government changes the course of our medicines policy with intention, Australia's pricing of patented pharmaceuticals is likely to follow inequitable US trends.

    Original languageEnglish
    Pages (from-to)240-242
    Number of pages3
    JournalMedical Journal of Australia
    Volume187
    Issue number4
    DOIs
    Publication statusPublished - 20 Aug 2007

    Fingerprint

    Dive into the research topics of 'Reference pricing for pharmaceuticals: Is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?'. Together they form a unique fingerprint.

    Cite this